Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Robitussin is a prominent brand of over-the-counter (OTC) cough and cold medications developed and marketed by Haleon. The product line is designed to treat various symptoms of the common cold and upper respiratory infections, primarily focusing on cough suppression and chest congestion relief. The brand features several formulations, including daytime and nighttime syrups. The daytime variants, such as Robitussin Maximum Strength DM, typically combine **dextromethorphan hydrobromide** (an antitussive) with **guaifenesin** (an expectorant). The nighttime variants, such as Robitussin Maximum Strength Nighttime DM, combine dextromethorphan with **doxylamine succinate**, a first-generation antihistamine that provides relief from runny nose and sneezing while also acting as a sedative. Haleon has conducted real-world evidence studies (e.g., NCT06716645) to evaluate the impact of these multi-symptom relief regimens on the health-related quality of life in adults with cough associated with the common cold.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Robitussin.